Mark E Pennesi1, David G Birch2, Jacque L Duncan3, Jean Bennett4, Aniz Girach5. 1. Casey Eye Institute, Oregon Health & Science University, Portland, Oregon. 2. Retina Foundation of the Southwest, Dallas, Texas. 3. Department of Ophthalmology, University of California, San Francisco, California. 4. Department of Ophthalmology, Perelman School of Medicine, Center for Advanced Retinal and Ocular Therapeutics, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania. 5. Nightstar Therapeutics, London, United Kingdom.
Abstract
PURPOSE: Choroideremia is an incurable, X-linked, recessive retinal dystrophy caused by loss of function mutations in the CHM gene. It is estimated to affect approximately 1 in 50,000 male patients. It is characterized by progressive degeneration of the retinal pigment epithelium, choroid, and photoreceptors, resulting in visual impairment and blindness. There is an unmet need in choroideremia, because currently, there are no approved treatments available for patients with the disease. METHODS: We review the patient journey, societal impact, and emerging treatments for patients with choroideremia. RESULTS: Its relative rarity and similarities with other retinal diseases in early years mean that diagnosis of choroideremia can often be delayed. Furthermore, its impact on affected individuals, and wider society, is also likely underestimated. AAV2-mediated gene therapy is an investigational treatment that aims to replace the faulty CHM gene. Early-phase studies reported potentially important visual acuity gains and maintenance of vision in some patients, and a large Phase 3 program is now underway. CONCLUSION: Choroideremia is a disease with a significant unmet need. Interventions that can treat progression of the disease and improve visual and functional outcomes have the potential to reduce health care costs and enhance patient quality of life.
PURPOSE:Choroideremia is an incurable, X-linked, recessive retinal dystrophy caused by loss of function mutations in the CHM gene. It is estimated to affect approximately 1 in 50,000 male patients. It is characterized by progressive degeneration of the retinal pigment epithelium, choroid, and photoreceptors, resulting in visual impairment and blindness. There is an unmet need in choroideremia, because currently, there are no approved treatments available for patients with the disease. METHODS: We review the patient journey, societal impact, and emerging treatments for patients with choroideremia. RESULTS: Its relative rarity and similarities with other retinal diseases in early years mean that diagnosis of choroideremia can often be delayed. Furthermore, its impact on affected individuals, and wider society, is also likely underestimated. AAV2-mediated gene therapy is an investigational treatment that aims to replace the faulty CHM gene. Early-phase studies reported potentially important visual acuity gains and maintenance of vision in some patients, and a large Phase 3 program is now underway. CONCLUSION:Choroideremia is a disease with a significant unmet need. Interventions that can treat progression of the disease and improve visual and functional outcomes have the potential to reduce health care costs and enhance patient quality of life.
Authors: Samuel G Jacobson; Artur V Cideciyan; Ramakrishna Ratnakaram; Elise Heon; Sharon B Schwartz; Alejandro J Roman; Marc C Peden; Tomas S Aleman; Sanford L Boye; Alexander Sumaroka; Thomas J Conlon; Roberto Calcedo; Ji-Jing Pang; Kirsten E Erger; Melani B Olivares; Cristina L Mullins; Malgorzata Swider; Shalesh Kaushal; William J Feuer; Alessandro Iannaccone; Gerald A Fishman; Edwin M Stone; Barry J Byrne; William W Hauswirth Journal: Arch Ophthalmol Date: 2011-09-12
Authors: Thomas J Heesterbeek; Hilde P A van der Aa; Ger H M B van Rens; Johannes W R Twisk; Ruth M A van Nispen Journal: Ophthalmic Physiol Opt Date: 2017-05-18 Impact factor: 3.117
Authors: Thomas K M Lee; Kerry E McTaggart; Paul A Sieving; John R Heckenlively; Alex V Levin; Jacquie Greenberg; Richard G Weleber; Patrick Y Tong; Edward F Anhalt; Berkley R Powell; Ian M MacDonald Journal: Can J Ophthalmol Date: 2003-08 Impact factor: 1.882
Authors: Matthew P Simunovic; Jasleen K Jolly; Kanmin Xue; Thomas L Edwards; Markus Groppe; Susan M Downes; Robert E MacLaren Journal: Invest Ophthalmol Vis Sci Date: 2016-11-01 Impact factor: 4.799
Authors: Eva K Fenwick; Peng Guan Ong; Ryan Eyn Kidd Man; Ching-Yu Cheng; Charumathi Sabanayagam; Tien Y Wong; Ecosse L Lamoureux Journal: JAMA Ophthalmol Date: 2016-10-01 Impact factor: 7.389
Authors: Luciano C Greig; Karen G Gutierrez; Jin Kyun Oh; Sarah R Levi; Edward Korot; Stephen H Tsang; Vinit B Mahajan Journal: Am J Ophthalmol Case Rep Date: 2022-04-20
Authors: Davide Ortolan; Ruchi Sharma; Andrei Volkov; Arvydas Maminishkis; Nathan A Hotaling; Laryssa A Huryn; Catherine Cukras; Stefano Di Marco; Silvia Bisti; Kapil Bharti Journal: Proc Natl Acad Sci U S A Date: 2022-05-06 Impact factor: 12.779
Authors: Nancy Aguilera; Tao Liu; Andrew J Bower; Joanne Li; Sarah Abouassali; Rongwen Lu; John Giannini; Maximilian Pfau; Chelsea Bender; Margery G Smelkinson; Amelia Naik; Bin Guan; Owen Schwartz; Andrei Volkov; Alfredo Dubra; Zhuolin Liu; Daniel X Hammer; Dragan Maric; Robert Fariss; Robert B Hufnagel; Brett G Jeffrey; Brian P Brooks; Wadih M Zein; Laryssa A Huryn; Johnny Tam Journal: Commun Biol Date: 2022-09-13
Authors: Alexandra V Garafalo; Artur V Cideciyan; Elise Héon; Rebecca Sheplock; Alexander Pearson; Caberry WeiYang Yu; Alexander Sumaroka; Gustavo D Aguirre; Samuel G Jacobson Journal: Prog Retin Eye Res Date: 2019-12-30 Impact factor: 21.198